Close

Taysha Gene Therapies (TSHA) Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. TSLA
2. SPY
3. GM
4. SPOT
5. AMZN
6. SHW
7. AAPL
8. IBM
9. MINN
10. NVDA


Go back to Taysha Gene Therapies (TSHA) Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program
(NASDAQ: TSHA) Delayed: 2.53 +0.07 (2.85%)
Previous Close $2.46    52 Week High $ 
Open $2.56    52 Week Low $ 
Day High $2.61    P/E N/A 
Day Low $2.48    EPS $ 
Volume 1,458,790